期刊文献+

重庆市六区(县)耐多药肺结核患者发现治疗现状分析 被引量:12

The analysis of current situation on the detection and treatment of MDR-TB patients in six districts and counties of Chongqing city
下载PDF
导出
摘要 目的通过分析重庆市6个区(县)的耐多药肺结核患者发现和治疗情况,为探索重庆市的耐药结核病防治模式提供科学依据。方法对三峡库区6个区(县)收集的1189例涂阳肺结核患者进行传统药敏试验,其中1015例新涂阳肺结核患者,174例耐多药肺结核高危人群;根据耐多药肺结核患者发现和治疗数据,分析不同类型肺结核患者中的耐多药肺结核检出率、菌株运输情况及确诊耐多药肺结核患者未纳入治疗的原因。结果1189例涂阳肺结核患者中,84例(7.1%)确诊为耐多药肺结核。不同性别耐多药检出率比较,男性为6.9%(61/883)、女性为7.5%(23/306),不同性别间差异无统计学意义(χ2=0.07,P〉O.05);不同年龄组间耐多药检出率比较,≤20岁、〉20~岁、41~岁、61~80岁分别为6.9%(7/102)、8.7%(25/286)、7.8%(39/499)、4.3%(13/302),不同年龄组问差异无统计学意义(χ2=2.15,P〉0.05);从患者分类来看,新涂阳肺结核患者的耐多药检出率为3.6%(37/1015),高危人群检出率为27.0%(47/174),差异有统计学意义(χ2=123.5,P〈0.01)。耐多药可疑患者留痰至开展药敏试验的总体时间间隔平均为90.9d(66.0-118.9d)。84例确诊耐多药肺结核患者中,22例纳入治疗,纳入治疗率为26.2%(22/84);62例未纳入治疗,经济困难为未纳入治疗的第一位原因,其患者占41.9%(26/62)。结论重庆市耐多药肺结核发现的筛查对象应为高危人群,应就近设立定点医院耐多药肺结核规范化诊疗管理点,并落实医保政策,解决患者的诊疗费用,以保障患者进行规范化治疗。 Objective For the purpose of providing scientific evidence for the prevention and treatment model of drug-resistant TB, we analyzed the current situation on the detection and treatment of MDR-TB patients of 6 dis- tricts and counties in Chongqing. Methods All 1189 smear-positive patients were collected from the 6 districts and counties of the 3 Gorges reservoir region.1015 cases were new smear-positive TB patients and 174 cases were from high risk patients of MDR-TB. The drug-susceptibility test results, transporting situation and the causes who were not included in the treatment were analyzed. Results Among 1189 smear-positive patients,84 cases(7, 1%)were diagnosed as MDR-TB. Comparing multidrug-resistant detection rate in different gender, the male was 6.9% (61/883), the female was 7.5% (23/306); there was no statistical differences between genders with the detection rate of multidrug-resistant(χ2=0.07, P〉0.05). Comparing different age groups,≤20 years,〉20 years- ,41 years- and 61-80 years old were 6.9% (7/102), 8. 7% (25/286), 7.8% (39/499), 4. 3% (13/302) respectively; there was no statistical differences between different age groups with the detection rate of multidrug-resistant(χ2 =2.15, P〈0. 05). From the point of patient classification, new smear-positive pulmonary tuberculosis patients with multi- drug-resistant detection rate was 3.6% (37/1015), the detection rate from high risk population was 27.0% (47/174), the difference was statistically significant (χ2= 123.5,P〈0.01). The overall time interval (d) for sus- pected multi-drug resistant patients between leave phlegm to carry out drug sensitive test was an average of 90. 9 d (66.0-118.9 d). In 84 cases of multi-drug resistant TB diagnosis, 22 cases received treatment, the treatment rate was 26.2% (22/84) ; and 62 cases were out of treatment and economic difficulties was the priority reason accounting for 41.9 %(26/62). Conclusion The screening for MDR-TB should target at the high risk population in Chongqing city, we should set up standardized diagnosis and treatment management points of MDR-TB nearby designated TB hospitals, and carry out medical insurance policy, addressing patient clinic costs, in order to ensure patients' s standardized treatment.
出处 《中国防痨杂志》 CAS 2013年第10期808-811,共4页 Chinese Journal of Antituberculosis
基金 "十一五"国家科技重大专项(2008ZX10003-007)
关键词 结核 药物疗法 抗药性 多种 细菌 重庆市 Tuberculosis, pulmonary/drug therapy Drug resistance, multiple, bacterial Chongqing city
  • 相关文献

参考文献8

二级参考文献23

  • 1唐神结.耐药结核病的综合治疗[J].中华临床医师杂志(电子版),2010,4(7):916-919. 被引量:13
  • 2杜长梅,王国斌,徐吉英,王国杰,胡惠义,甄新安,李爱华,孙占强,闫国蕊.河南省第二轮结核病耐药监测及耐药趋势研究[J].中国防痨杂志,2006,28(2):95-100. 被引量:26
  • 3蒙志好,李勇,张锡贵.肺结核患者住院费用调查研究[J].中国医院统计,2006,13(4):333-335. 被引量:7
  • 4Treatment of tuberculosis: guidelines for national programmes, 3rd ed. Geneva:World Health Organization, 2003(WHO/CDS/ TB/2003. 313).
  • 5Ait-Khaled N, Enarson DA. Tuberculosis: a manual for medical students. Geneva: World Health Organization, 2003 (WHO/ CDS/TB/99. 272).
  • 6Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009. Geneva: World Health Organization, 2009 (WHO/HTM/TB/2009.411 ).
  • 7White VL, Moore-Gillon J. Resource implications of patients with muhidrug resistant tuberculosis [J]. Tharax, 2000, 55 (11): 962-963.
  • 8Rajbhandary SS, Marks SM, Bock NN. Cost of patients hospi- talized for multidrug-resistant tuberculosis[J]. Int J Tuberc lung Dis, 2004,8(8) : 1012-1016.
  • 9中国防痨协会.耐药结核病化学治疗指南[M].北京,2008.
  • 10WHO,Guidelines for the programmatic managemet of drug-resist- ant tuberculosis [ R ]. Geneva : World Health Organization,2008.

共引文献85

同被引文献112

引证文献12

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部